CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma
Trial Parameters
Brief Summary
This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.
Eligibility Criteria
Inclusion Criteria: 1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria; 2. The patient is at least 18 years old; 3. Participate in CXCR4 PET/MRI imaging within 15 days before surgery; 4. Surgical resection of glioma lesion tissue can be used for pathological analysis; 5. The patient voluntarily participates and signs the informed consent form. Exclusion Criteria: 1. Pregnant or breastfeeding patients; 2. The image quality of the imaging is poor and cannot be used for diagnosis and evaluation; 3. Molecular typing was not determined by histologic examination; 4. patients with claustrophobia; 5. Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.